Some people taking the combination drug had elevated transaminases; the combination drug should be used with caution for people with advanced liver disease and liver function should be measured for the first three months for all people starting the combination drug. People starting the combination have respiratory discomfort, and some children taking the combination drug developed cataracts.<unk>  may interfere with hormonal contraceptives. Dosage of the combination drug should be reduced if the person is taking a drug that inhibits CYP3A, and inducers of CYP3A should not be used concomitantly.
Lumacaftor/ivacaftor
Elexacaftor/tezacaftor/ivacaftor
Beclometasone/formoterol/glycopyrronium bromide
Mometasone/formoterol
Fluticasone/salmeterol
Beclometasone/formoterol
Lifitegrast
Ivacaftor